Korea-Israel collaboration, supported by KORIL-RDF, pairs Protai's AI-powered structural proteomics with Standigm's generative drug design to tackle selectivity - a central challenge in targeted protein degradation SEOUL, Republic of Korea and TEL AVIV, Israel, Sept. 16, 2026 /PRNewswire/ -- Standigm, an AI-driven drug discovery company, and Protai, a proteomics and AI-based drug discovery company, today announced a joint research and development program to build an integrated platform for the d

BOSTON, Sept. 16, 2026 /PRNewswire/ -- Radhika Saran, Cleo Pontone, and Sophia DeVito, students at Harvard University, have been named the U.S. National Winners of the James Dyson Award 2026 for their invention, Rumble Rims. The low-cost infrared eye-tracking headset is designed to help schools screen for possible concussions in about 60 seconds, bringing objective neurological insight into the sideline moments where coaches, athletes, and families often need clarity most. Continue Reading Rumbl

ATLANTA, Sept. 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (" Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (" Alzheimer's"), bipolar disorder (" BD"), major depressive disorder (" MDD") and post-traumatic stress disorder (" PTSD"), today announced that it has received a notification letter (the " Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (" Nasd

Access to the first and only FDA-approved neuroimmune modulation therapy for rheumatoid arthritis continues to grow across the United States VALENCIA, Calif. , Sept. 16, 2026 /PRNewswire/ -- SetPoint Medical, a commercial-stage medical technology company dedicated to improving care for people living with chronic autoimmune diseases, today announced that Oregon Health & Science University (OHSU) is the first health system in the Pacific Northwest to treat a patient with the SetPoint System. The t

NEWTON, Mass. and WÄDENSWIL, Switzerland, Sept. 16, 2026 /PRNewswire/ -- GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the appointment of Andrea Matthews as Chief Business Officer. "We are delighted to welcome Andrea to GlycoEra's leadership team," said Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra. "Andrea brings deep strategic experience in public biotech companies and trans

Six years after Seer’s foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, disease biology and population healthREDWOOD CITY, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer in deep, unbiased proteomics, today announced that its Proteograph® Product Suite has been used by researchers in more than 100 peer-reviewed scientifi

Long-acting injectables (LAIs) offer an opportunity to improve adherence and potential outcomes for patients with schizophreniaLongActingImpact.com is a new resource center designed to support clinicians in having informed treatment conversations with those living with schizophreniaAs a leader in neuroscience, Teva is committed to supporting clinicians by providing evidence-based resources which could help improve schizophrenia care PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GL

Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy® Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated SOLAN

NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health. The botanical formulations pair Shatavari for menopausal support with sustained-release ginger for menstrual comfort. The findings come amid growing interest in evidence-based women’s health solutions and ahead of World Menopause Month and SupplySide Global

WALTHAM, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc. (Nasdaq: KLRA) (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced participation in the following investor conferences: Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare ForumWednesday, September 23, 2026, 9:40 a.m. ETFireside Chat with Jamie Coleman, Chief Commercial Officer Stifel 2026 Virtual Cardiometabolic ForumWednesd